Description
Research Metrics
📈
3–5×
Synergistic GH Release
Combined vs. either peptide alone
🎯
Selective
Ipamorelin Profile
No cortisol/prolactin/ACTH spike
📚
20+
Combination Studies
Peer-reviewed GHRH+GHRP research
⏱️
30 min
GH Pulse Duration
Extended release vs. GHRP alone
🧬
2
Receptor Systems
GHRHR + GHSR-1a simultaneous
🏥
Phase 2
CJC Clinical Data
Human trials completed — ConjuChem
Mechanism of Action
How CJC-1295 / Ipamorelin Works
CJC-1295 — GHRH
GHRH Receptor Agonist
Growth Hormone Releasing Hormone Receptor
- Binds pituitary GHRH receptors (GHRHR)
- Stimulates GH synthesis and release
- No DAC = physiological pulsatile pattern
IPAMORELIN — GHRP
Ghrelin Receptor Agonist
GHSR-1a Selective Agonist
- Selective GHSR-1a binding
- GH secretion without cortisol/prolactin rise
- Pentapeptide — smallest effective GHRP
COMBINED — SYNERGY
Dual Pathway Activation
Simultaneous GHRHR + GHSR-1a
- 3–5× greater GH release than either alone
- Amplified pulse amplitude + frequency
- Most studied GHRH/GHRP combination
Synergistic mechanism: CJC-1295 and Ipamorelin act on completely separate receptor systems. Simultaneous activation produces a multiplicative — not additive — increase in GH secretion in rodent models. (Ionescu & Frohman, J Clin Endocrinol 2006)
Preclinical Data
What Research Has Shown
⚠️ CJC-1295 with DAC reached Phase 2 human trials by ConjuChem. The No DAC + Ipamorelin combination is primarily preclinical rodent data. GH-axis manipulation carries theoretical long-term risks in humans.
3–5×
GH Release
Combined vs. either alone
Phase 2
CJC Human Trial
ConjuChem — completed
99%
GH Selective
Ipamorelin vs. cortisol
⚠️ CJC-1295 has Phase 2 human data (with DAC version). The No DAC + Ipamorelin combination is rodent-primary. GH axis research in humans requires careful consideration of IGF-1 and long-term effects.
Research Applications
Areas Studied in Preclinical Research
GH Axis Research
Pituitary Biology
The primary research application — studying pulsatile GH secretion, GH axis regulation, and pituitary responsiveness in rodent and cell models.
Most studied GHRH+GHRP combination in literature
J Clin Endocrinol (2006) →
Body Composition Research
Lean Mass & Metabolism
Rodent studies examining effects of enhanced GH pulsatility on lean body mass, fat oxidation, and metabolic markers over time.
GH-deficient rodent body composition models
Endocrinology (1998) →
Bone Density Research
Skeletal Biology
GH and IGF-1 are established bone metabolism regulators. Research examines whether enhanced GH pulsatility affects bone density markers in GH-deficient models.
Bone mineral density endpoints in rodent models
J Endocrinology →
GH Deficiency Models
Therapeutic Research
Both peptides studied in GH-deficient animal models. CJC-1295 reached Phase 2 trials in GH-deficient adults by ConjuChem Biotechnologies (Canada).
Phase 2 completed — adults with GHD
J Clin Endocrinol →
Synergistic Combination
Why These Two Peptides Together?
| Peptide | Receptor | Mechanism | Effect |
|---|---|---|---|
| CJC-1295 (No DAC) | GHRHR (pituitary) | GHRH analog — stimulates GH synthesis | Amplifies GH pulse size |
| Ipamorelin | GHSR-1a (ghrelin) | Selective GHRP — GH only | Increases GH pulse frequency |
| Combined | Both simultaneously | Synergistic dual-pathway | 3–5× greater GH vs. either alone |
💡 Ipamorelin's key advantage: Unlike GHRP-2 and GHRP-6, Ipamorelin does NOT significantly increase cortisol, prolactin, or ACTH — making it the most selective GHRP for isolated GH secretion research. (Raun K et al., Endocrinology 1998)
Safety Data
Safety Profile from Research
📊 Preclinical Safety Summary
Ipamorelin — cortisolNo significant increase
Ipamorelin — prolactinNo significant increase
CJC-1295 Phase 2 (DAC)No serious adverse events
Acute toxicity (rodent)None observed
⚠️ Regulatory & Risk Considerations
FDA statusUnapproved — both peptides
WADA statusBanned — GH secretagogues
IGF-1 elevationTheoretical cancer concern
Long-term GH axisUnknown in humans
💡 Ipamorelin's safety advantage vs. older GHRPs: no significant cortisol or prolactin elevation at research doses (Raun K, 1998). CJC-1295 Phase 2 showed a favorable safety profile. Long-term GH axis effects in humans are unknown and require caution.
Compound Information
Technical Specifications
| CJC-1295 (No DAC) CAS | 863288-34-0 |
| Ipamorelin CAS | 170851-70-4 |
| CJC-1295 Molecular Weight | 3,367.9 g/mol |
| Ipamorelin Molecular Weight | 711.9 g/mol |
| Ipamorelin Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide) |
| Purity (Euno Labs) | 99.3% — HPLC Verified (both) |
| Appearance | White lyophilized powder |
| Storage (lyophilized) | Room temp short-term; –20°C long-term |
| Storage (reconstituted) | 2–8°C, use within 4–6 weeks |
Lab Protocol
Reconstitution Protocol
- Add 2mL bacteriostatic water to the combination vial
- Inject slowly down the inside vial wall — do not spray onto powder
- Gently swirl until fully dissolved
- If separate vials: reconstitute each with 1mL BAC water independently
- Store at 2–8°C after reconstitution
- Use within 4–6 weeks
Separate vials allow flexible dosing ratios. CJC-1295 and Ipamorelin dissolve quickly — both should be fully dissolved within 60 seconds of gentle swirling.
Sources & References
Peer-Reviewed Research
Journal of Clinical Endocrinology & Metabolism — 2006
CJC-1295 increases GH and IGF-1 in healthy adults: A Phase 2 trial
View Source →
Growth Hormone & IGF Research — 1999
Growth hormone-releasing peptides and their analogs
View Source →
⚗️ For Research Use Only
Sold strictly for research and educational purposes. Not approved by the FDA for human consumption or therapeutic use. All research findings are for educational reference only and do not constitute medical advice. By purchasing you confirm you are a qualified researcher.
Reviews
There are no reviews yet.